Gordon Kenneth B, Strober Bruce E
Professor of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Associate Professor and Vice Chair, University of Connecticut Health Center, Farmington, Connecticut.
Semin Cutan Med Surg. 2014 Mar;33(2 Suppl 2):S20-3. doi: 10.12788/j.sder.0067.
Psoriasis is now recognized as an immunologically mediated systemic disease that may be expressed in cutaneous and joint symptoms. Medications that were once thought to control psoriasis by reducing keratinocyte proliferation are now known to act on immunologic pathways. In recent years, the emerging understanding of immunologic pathways in psoriasis has resulted in the use of biologic medications (eg, inhibitors of tumor necrosis factor) to treat psoriasis. More recently, other pathophysiologic pathways have been identified that have the potential to expand the therapeutic armamentarium. Other avenues of research within the past decade have demonstrated that a range of health risks and comorbid inflammatory diseases are associated with psoriasis, and they have the potential to increase morbidity and mortality and adversely affect quality of life.
银屑病现在被认为是一种免疫介导的全身性疾病，可能表现为皮肤和关节症状。曾经被认为通过减少角质形成细胞增殖来控制银屑病的药物，现在已知是作用于免疫途径。近年来，对银屑病免疫途径的新认识导致了生物药物（如肿瘤坏死因子抑制剂）的使用来治疗银屑病。最近，已确定了其他病理生理途径，有可能扩大治疗手段。过去十年中的其他研究途径表明，一系列健康风险和合并的炎症性疾病与银屑病相关，它们有可能增加发病率和死亡率，并对生活质量产生不利影响。
